ArriVent BioPharma, Inc.

The momentum for this stock is not very good. ArriVent BioPharma, Inc. is not a good growth stock. ArriVent BioPharma, Inc. is not very popular among insiders. Tradey thinks it is not wise to invest in ArriVent BioPharma, Inc..

News

The Goldman Sachs Group Increases ArriVent BioPharma (NASDAQ:AVBP) Price Target to $38.00

Ticker Report ArriVent BioPharma (NASDAQ:AVBP - Get Free Report) had its target price increased by equities researchers at The Goldman Sachs Group from $28.00 to $38.00 in a research report issued on Tuesday...\n more…

ArriVent BioPharma (NASDAQ:AVBP) Stock Rating Reaffirmed by Oppenheimer

Zolmax ArriVent BioPharma (NASDAQ:AVBP - Get Free Report)s stock had its "outperform" rating restated by investment analysts at Oppenheimer in a research note issued on Tuesday, Benzinga reports...\n more…

ArriVent BioPharma (NASDAQ:AVBP) Price Target Raised to $38.00

Zolmax ArriVent BioPharma (NASDAQ:AVBP - Get Free Report) had its price target increased by The Goldman Sachs Group from $28.00 to $38.00 in a report released on Tuesday, Benzinga reports. The firm...\n more…

ArriVent Biopharma price target raised by $6 at Citi, here's why

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

ArriVent BioPharma (NASDAQ:AVBP) PT Raised to $36.00

Zolmax ArriVent BioPharma (NASDAQ:AVBP - Free Report) had its price target increased by HC Wainwright from $30.00 to $36.00 in a research report released on Tuesday, Benzinga reports. They currently have a...\n more…

ArriVent BioPharma (NASDAQ:AVBP) Shares Gap Up Following Analyst Upgrade

Ticker Report ArriVent BioPharma, Inc. (NASDAQ:AVBP - Get Free Report) gapped up prior to trading on Tuesday after The Goldman Sachs Group raised their price target on the stock from $28.00 to $38.00. The stock...\n more…